Cystatin C and preclinical lesions in the target organs of hypertensive patients
- Authors: Oshchepkova EV1, Dmitriev VA1, Titov VN1
-
Affiliations:
- Институт клинической кардиологии им. А.Л. Мясникова ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
- Issue: Vol 86, No 9 (2014)
- Pages: 31-37
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31545
- ID: 31545
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
E V Oshchepkova
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
V A Dmitriev
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
V N Titov
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
References
- Filler G., Bokenkamp A., Hofmann W. et al. Cystatin C as a marker of GFR - history, indications, and future research. Clin Biochem 2005; 38: 1-8.
- Grubb A., Löfberg H. Human γ-trace, a basic microprotein: Amino acis sequence and presence in the adenohypophysis. Proc Natl Acad Sci USA 1982; 79: 3024-3027.
- Simmonsen O., Grubb A., Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985; 45: 97-101.
- Battistoni A., Rubbatu S., Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol 2012; 157: 160-168.
- Luc G., Bard J.M., Lesueur C. et al. Plasma cystatin-C and development of coronary heart disease: the PRIME study. Atherosclerosis 2006; 185: 375-380.
- Shlipak M.G., Sarnak M.G., Katz R. et al. Cystatin C and the Risk of death and cardiovascular events among elderly persons. NEJM 2005; 352: 2049-2060.
- Emberson J.R., Haynes R., Dasgupta T. et al. Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J Int Med 2010; 268: 145-154.
- Toft I., Solbu M., Kronburg J. et al. Cystatin C as a risk factor cardiovascular events and all-cause mortality in the general population. Nephrol Dial Transplant 2012; 27: 2780-2787.
- Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. ВНОК 2008 г.
- KDIGO 2102 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 1 (1): 51.
- Shankar A., Teppala S. Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease. J Am Soc Hypertens 2011; 5 (5): 378-384.
- Mena C., Robles N.R., de Prado M. et al. Cystatin C and blood pressure: Results of 24 h ambulatory blood pressure monitoring. Eur J Int Med 2010; 21: 185-190.
- Чазова И.Е., Ощепкова Е.В., Чихладзе Н.М. Артериальная гипертония. Принципы диагностики и лечения (пособие для врачей). М 2005: 35.
- Matsushita K., Mahmodi B.K., Woodward M. et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307: 1941-1951.
- Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
- Grundy S.M. Inflammation, Hypertension and the metabolic syndrome. JAMA 2003; 22: 3000-3002.
- ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-2219.
- Magister S., Kos J. Cystatins in immune system. J Cancer 2013; 4 (1): 45-56.
- Smith E.R. Cystatin C - more than a filtration marker? Atherosclerosis 2013; 230: 73-75.
- Eriksen B.O., Mathisen U.D., Melsom T. et al. The Role of Cystatin C in Improving GFR Estimation in the General Population. Am J Kidney Dis 2012; 59 (1): 32-40.
- Rokadia H.K., Agarwal S. Serum cystatin C and emphysema: results from the Nutrtion Examination Survey (NHANES). Lung 2012; 190 (3): 283-290.
- Salgado J.V., Souza F.L., Salgado B.J. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance or sequence? J Cardiol 2013; 62: 331-335.
- Joachim H., Shlipak M., Chertow G.M. et al. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Cardiac Fail 2006; 12 (8): 601-607.
- Aumann N., Baumeister S., Werner A. et al. Inverse association of estimated cystatin C-and creatinine-based glomerular filtration rate with left ventricular mass: Results from the Study of Health in Pomerania. Int J Cardiol 2013; 167 (6): 2786-2791.
- Knight E.L., Verhave J.C., Spielgelman Е. et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421.
- Urbonaviciene G., Shi G.P., Urbonavicus S. et al. Higher Cystatin C levels predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis 2011; 216: 440-445.
Supplementary files
